Journal
IMMUNOLOGIC RESEARCH
Volume 48, Issue 1-3, Pages 122-146Publisher
HUMANA PRESS INC
DOI: 10.1007/s12026-010-8172-z
Keywords
Gamma-herpesviruses; Vaccine; EBV; KSHV; MHV-68
Categories
Funding
- NIH [DE18337, AI42927, CA148250, T32 AI49823, F32AI084327, DE19085, DE15752]
- Stop Cancer Foundation
Ask authors/readers for more resources
Due to the oncogenic potential associated with persistent infection of human gamma-herpesviruses, including Epstein-Barr virus (EBV or HHV-4) and Kaposi's sarcoma-associated herpesvirus (KSHV or HHV-8), vaccine development has focused on subunit vaccines. However, the results using an animal model of mouse infection with a related rodent virus, murine gamma-herpesvirus 68 (MHV-68, gamma HV-68, or MuHV-4), have shown that the only effective vaccination strategy is based on live attenuated viruses, including viruses engineered to be incapable of establishing persistence. Vaccination with a virus lacking persistence would eliminate many potential complications. Progress in understanding persistent infections of EBV and KSHV raises the possibility of engineering a live attenuated virus without persistence. Therefore, we should keep the option open for developing a live EBV or KSHV vaccine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available